Stryker Extends Settlement Deadline
By Anderson, Cummings & Drawhorn, LLP on April 02, 2015
By Anderson, Cummings & Drawhorn, LLP on April 02, 2015
The Stryker Corp. ABG II and Rejuvenate modular hip implant claim enrollment deadline was extended to April 17, 2015. Claims must be filed by 5:00 p.m. EST.
Table of Contents
The agreement pays out a base compensation of $300,000. It also provides additional payments up to $600,000 for serious complications, including post-operative infections, the need for additional surgeries, hip dislocations, femur fractures, heart attacks, strokes, lost wages and death.
Unfortunately, the Stryker hip implant devices carried serious risks including reports of unusually high rates of failure.
The defect was linked to metal on metal bearings, which can produce small metallic wear debris or corrosion can take place with the constant movement between the two metal surfaces. Metal toxicity, or metallosis, can lead to severe joint pain, implant failure and deterioration of the bone around the implant.
The company pulled the Rejuvenate and ABG II hip implant devices off of the market in 2012. By then, more than 20,000 of the devices had been implanted in people across the country.
Serious Complications Include:
Dangerous medical devices harm people like you every day, and we understand the importance of results. Our law firm is proud to fight for the rights of Texans against companies who have manufactured these defective hip implants. A Fort Worth personal injury lawyer from our firm will use our resources and knowledge to build a strong case in your favor, and that will help you obtain the MAXIMUM amount of compensation you deserve for your pain and suffering.
Call (817) 920-9000 to schedule your free consultation today.
This page has been written, edited, and reviewed by a team of legal writers following our comprehensive guidelines. This page was approved by attorney Seth Anderson, whose team has more than 50 years of combined legal experience in helping victims of personal injury seek justice.
Key Takeaways Gastroparesis occurs when stomach muscles slow or stop moving food through the digestive tract. Semaglutide medications, such as Ozempic, slow stomach emptying to regulate blood sugar. Patients often report persistent nausea or repeated vomiting after starting Ozempic. In some patients, semaglutide may slow gastric motility too much. Product...
Read Article
Key Takeaways The Trulicity lawsuit refers to product liability claims against dulaglutide manufacturer. Eligibility depends on proof of use and a diagnosed injury linked to the medication. Plaintiffs allege inadequate warnings about serious gastrointestinal risks and potential long-term complications. Federal courts consolidate similar GLP-1 claims into multidistrict litigation to manage...
Read Article
Key Takeaways Trulicity treats Type 2 diabetes by slowing digestion and increasing insulin release, which can cause gastrointestinal symptoms. Common effects include nausea, diarrhea, abdominal pain, and decreased appetite. Serious risks include thyroid tumors, pancreatitis, gastroparesis, kidney injury, vision changes, and severe allergic reactions. Severe abdominal pain, persistent vomiting, breathing...
Read ArticleTell us about your accident and your injuries. An injury lawyer from our team will call and provide you with a free evaluation of your case. If we can help, and you are unable to travel, we will come to your home, office, or hospital. It’s easy – let’s get started.
Email us anytime and we will get back to you.
Our attorneys will come to your home, office or hospital at your convenience.
Our team is ready and waiting to help you today.